Shire’s Exit Strategy from Japan Provides Bayer with Exclusive Product Rights
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 44 (Table of Contents)
Published: 4 Feb-2004
DOI: 10.3833/pdr.v2004.i44.834 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Shire Pharmaceuticals has sold Bayer the exclusive rights to develop, market and sell FOSRENOL® in Japan in a deal worth up to US$70 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS